Keyphrases
Whole-body
100%
In Vivo Molecular Imaging
100%
Neuroendocrine Malignancies
100%
PET Radiotracers
100%
Prostate-specific Antigen
83%
18F-fluorodeoxyglucose (18F-FDG)
83%
Neuroendocrine Differentiation
66%
Radiolabeled Somatostatin Analogs
66%
Neuroendocrine Features
50%
Adenocarcinoma
33%
Prostate Cancer
33%
Gallium-68
33%
Neuroendocrine Tumor
33%
Prostatic Adenocarcinoma
33%
Nave
16%
Differential Diagnosis
16%
Molecular Imaging
16%
Clinical Management
16%
Published Data
16%
Carcinoma
16%
Well-differentiated
16%
Pathologic
16%
Newly Diagnosed
16%
Clinical Scenarios
16%
Disease Spectrum
16%
Somatostatin Analogs
16%
Positron Emission Tomography-computed Tomography (PET-CT)
16%
Antigen Expression
16%
Preclinical Imaging
16%
Nuclear Imaging
16%
Positron
16%
Hormonal Therapy
16%
Prostatic Tumor
16%
Pancreatic Neuroendocrine Tumors (pNETs)
16%
Neuroendocrine Carcinoma
16%
Oncologic Imaging
16%
Biological Imaging
16%
Nuclear Molecular Imaging
16%
Cellular Glucose Metabolism
16%
Medicine and Dentistry
Cancer
100%
Radioactive Tracer
100%
Molecular Imaging
100%
Positron Emission Tomography
100%
Somatostatin Derivative
83%
Fluorodeoxyglucose F 18
83%
Prostate Specific Membrane Antigen
83%
Neuroendocrine Differentiation
66%
Adenocarcinoma
33%
Prostate Cancer
33%
Neuroendocrine Tumor
33%
Prostate Adenocarcinoma
33%
Gallium 68
33%
Disease
16%
Glucose Metabolism
16%
Differential Diagnosis
16%
Carcinoma
16%
Clinical Management
16%
Hormone Therapy
16%
Prostate Tumor
16%
Positron Emission Tomography-Computed Tomography
16%
Antigen Expression
16%
Fluorine-18
16%
Clinical Imaging
16%
Nuclear Medicine
16%
Neuroendocrine Carcinoma
16%
Pharmacology, Toxicology and Pharmaceutical Science
Tracer
100%
Somatostatin Derivative
83%
Fluorodeoxyglucose F 18
83%
Prostate Specific Membrane Antigen
83%
Adenocarcinoma
33%
Prostate Cancer
33%
Gallium 68
33%
Prostate Adenocarcinoma
33%
Neuroendocrine Tumor
33%
Disease
16%
Carcinoma
16%
Prostate Tumor
16%
Fluorine 18
16%
Hormone Cancer Therapy
16%
Neuroendocrine Carcinoma
16%